WSFS
CLDX icon

Wilmington Savings Fund Society’s Celldex Therapeutics CLDX Stock Holding History

Wilmington Savings Fund Society’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60.8K Hold
1,633
– – ﹤0.01% 854
2026
Q1 		$51.8K Hold
1,633
– – ﹤0.01% 876
2025
Q4 		$44.4K Hold
1,633
– – ﹤0.01% 902
2025
Q3 		$42.2K Buy
+1,633
New +$37.8K ﹤0.01% 921

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wilmington Savings Fund Society's CLDX Position: Q2 2026 in Review

Wilmington Savings Fund Society held its Celldex Therapeutics (CLDX) position steady in Q2 2026 at 1,633 shares worth $60.8K. The position accounts for ﹤0.01% of the portfolio, ranked #854.

Wilmington Savings Fund Society first reported a position in CLDX in Q3 2025 and has held it in 4 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Wilmington Savings Fund Society held 1,633 shares of Celldex Therapeutics worth $60.8K as of Q2 2026.
  • Wilmington Savings Fund Society left its Celldex Therapeutics share count unchanged in Q2 2026.
  • Celldex Therapeutics made up ﹤0.01% of Wilmington Savings Fund Society's portfolio in Q2 2026, its #854 holding.
  • Wilmington Savings Fund Society first reported a position in Celldex Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Wilmington Savings Fund Society's 13F filing for Q2 2026, filed 28 Jul 2026.